S100A10 and Cancer Hallmarks: Structure, Functions, and its Emerging Role in Ovarian Cancer.
Tannith M NoyeNoor A LokmanMartin K OehlerCarmela RicciardelliPublished in: International journal of molecular sciences (2018)
S100A10, which is also known as p11, is located in the plasma membrane and forms a heterotetramer with annexin A2. The heterotetramer, comprising of two subunits of annexin A2 and S100A10, activates the plasminogen activation pathway, which is involved in cellular repair of normal tissues. Increased expression of annexin A2 and S100A10 in cancer cells leads to increased levels of plasmin-which promotes the degradation of the extracellular matrix-increased angiogenesis, and the invasion of the surrounding organs. Although many studies have investigated the functional role of annexin A2 in cancer cells, including ovarian cancer, S100A10 has been less studied. We recently demonstrated that high stromal annexin A2 and high cytoplasmic S100A10 expression is associated with a 3.4-fold increased risk of progression and 7.9-fold risk of death in ovarian cancer patients. Other studies have linked S100A10 with multidrug resistance in ovarian cancer; however, no functional studies to date have been performed in ovarian cancer cells. This article reviews the current understanding of S100A10 function in cancer with a particular focus on ovarian cancer.
Keyphrases
- extracellular matrix
- papillary thyroid
- poor prognosis
- case control
- gene expression
- randomized controlled trial
- squamous cell carcinoma
- binding protein
- endothelial cells
- systematic review
- mass spectrometry
- cell migration
- lymph node metastasis
- young adults
- vascular endothelial growth factor
- long non coding rna
- high resolution
- childhood cancer
- meta analyses